Prospective Observation of Cardiac Safety With Proteasome Inhibition

Trial Profile

Prospective Observation of Cardiac Safety With Proteasome Inhibition

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Bortezomib (Primary) ; Carfilzomib (Primary)
  • Indications Heart failure; Multiple myeloma
  • Focus Adverse reactions
  • Acronyms PROTECT
  • Most Recent Events

    • 18 Apr 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Aug 2017.
    • 08 Dec 2014 Planned primary completion date changed from 1 Jul 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
    • 08 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top